OMI Scores Major Grant To Explore Genetic Underpinnings and Alternative Therapies for Chronic Fatigue Syndrome (ME/CFS)
The Open Medicine Institute is fostering a new health care model by integrating direct patient involvement with a multi-disciplinary, big data technology approach to advance the understanding of complex diseases and directly improve outcomes. Linda Tannenbaum, Executive Director of the Open Medicine Institute
The Open Medicine Institute announced today they’ve received over $1,000,000 to investigate the genetic underpinnings of chronic fatigue syndrome (ME/CFS) and explore new treatments. One grant from the Edward P. Evans Foundation will fund most intensive exploration of genes and gene expression yet in this disease. Another from the Neuro-Immune -Disease- Alliance ( NIDA) will explore a promising herbal treatment using molecular profiling.
The gene study is particularly gratifying given the mounting evidence that, even with all its presumed subsets, chronic fatigue syndrome has a very strong genetic component.
Using newly developed techniques never applied to ME/CFS and featuring one of the top investigators in the field, the Evans Foundation grant will fund intensive investigations into the HLA regions of the genome, methylation and other aspects as well as whole genome sequencing.
Bedrock of the Immune System- The HLA Genes
When invaders enter the body they’re met by antigen presenting cells (dendritic cells, macrophages, some B-cells, etc.) that promptly gobble them up and then like warriors displaying trophies put a bit of them on the outside of their cells. They then swim to the lymph nodes so that T-cells can have a looksie. If the T-cells decide the APC’s have found a pathogen they mount an immune response that usually wipes it out.
That part of the cell that recognizes and then mounts the viral proteins on its surface is the HLA antigen. If the HLA displays the wrong part of the pathogen or doesn’t display any part of it, the pathogen goes on its merry way unimpeded by a major branch of the immune system. Without those little HLA messengers we’d be at the mercy of the pathogens in our midst.
HLA’s also encode portions of the complement system (one part of which is activated in ME/CFS), protect against cancers and may be involved in autoimmune disorders.
Several studies have suggest HLA problems may be present in ME/CFS. A 2011 study suggested HLA deficiencies were responsible for the low natural killer cell cytotoxicity in this disorder and a 2005 study suggested ME/CFS was associated with a specific HLA genotype.
The HLA genes, with their huge impact on immune functioning, are of major interest but the malleability that allows them to recognize virtually any pathogen, has made this portion of the genome particularly hard to characterize.
Enter Ron Davis – Uber Genome ‘Techonologist’
Enter Ron Davis of Stanford, Director of the Genome Technology Center at Center, of the pre-eminent geneticists of our times. More than just a geneticist, Davis is an inventor who holds over 40 biotechnological patents and has authored over 400 papers. The winner of the $500,000 2011 Gruber Genetics prize for his breakthroughs in the ‘development and application of recombinant-DNA techniques, if Davis can’t find a tool to do what he wants, his team simply develops one.
Upon winning the Dickson Prize, Davis was cited for his “great positive impact on a broad swath of biomedical research”. The Dickson Foundation noted that he and his “students, postdoctoral fellows, and technicians in his laboratory have developed many of the techniques currently used in academic and industrial biotechnology laboratories”. Davis is clearly a new and very important asset to the ME/CFS research community.
THe HLA technology being used is newly developed and highly touted and particularly applicable since HLA codes for the highly variable, immune-related region of DNA. Both of these characteristics make them more likely than routine sequencing to show something of value in ME/CFS. Dr. Kogelnik
Now Kogelnik and Davis will be using their newly minted technology to explore a heretofore obscured part of our genome. Both Kogelnik and Davis believe this area is ripe for exploration in ME/CFS and if their hunch is correct, this study could open an entirely new window on this disease.
Given the critical role of DNA methylation in gene expression and cell differentiation, it seems obvious that errors in methylation could give rise to a number of devastating consequences, including various diseases. The Role of Methylation in Gene Expression.
Methylation simply adds a ‘methyl group’ to strands of DNA but that little addition can change everything because that methyl group can determine whether an gene will express itself or not. The finding that highly methylated regions in the genome are mostly silent gave way to the realization that methylation played a key role in gene expression.
Epigenetics looks at whether something (aka methylation) came along to change the expression of the genes we are borne with. On May 16th, the CFIDS Association of America’s webinar on epigenetics will explore whether methylation or other processes have turned on or off key genes that exist at stress -immune response interface. McGowan, the CAA’s researcher, believes epigenetic mechanisms are disrupting immune responses in ME/CFS.
Methylation has also started off on a preliminary but promising foot with a 2011 CDC study suggesting that methylation and other processes may impair serotonergic neurotransmission, an interesting finding given the CFIDS Associations Biovista project finding that two serotonin effecting drugs (not yet named) may be useful in this disorder.
The OMI study is going to blast the field of methylation in ME/CFS wide open. With their focus on HLA and methylation genes the OMI will be taking a deep dive into two virtually untouched and very promising areas in ME/CFS genetics.
Beside the HLA and methylation projects, whole genome sequencing will be applied to some individuals and many others will be the recipients of a focus on parts of the genome (inflammatory, immune, signaling. etc.) Kogelnik believes are in play in ME/CFS.
One part of the project will feature one of Kogelnik’s favorite techniques; contrasting the results of responders to Rituximab and valganciclovir and non-responders in an attempt to understand why these drugs area working in some individuals and not others. Finding genetic differences potentially gives Kogelnik a straight line to a biomarker.
By the time the study is done approximately 1,000 ME/CFS patients will have taken part. This kind of data gathering on such a grand scale is rare in ME/CFS.
Moringa oleifera Trial
The OMI will also conduct the first of what will hopefully be a series of studies examining untested but promising natural therapies. Called the ‘miracle tree’ Moringa oleifera has been proposed to having antibiotic, antitrypanosomal, hypotensive, antispasmodic, antiulcer, anti-inflammatory, hypocholesterolemic, and hypoglycemic activities but few studies have been done.
This is what Dr. Kogelnik had to say about the Moringa trial.
We had heard a number of promising but VERY anecdotal stories of recovery with this substance. Like many natural (unregulated) substances it was completely untested scientifically in ME/CFS. That combined with the claimed boosting of NK cell function (and the relatively low cost of doing a pilot with this substance) made it a great first target to illustrate how low-budget science can also be beneficial in this field and needs to be done. We hope to apply this method to other potential candidate substances as we move forward with MERIT.
The Open Medicine Institutes ambitious OMI-MERIT program for ME/CFS is off to a good start with this major grant. They aim to speed up the pace of ME/CFS research and treatment findings by applying a ‘big data’ approach. Expect more from the OMI soon.
Support This Great Website !
Like the blog? Make sure you don’t miss another by registering for our ME/CFS and Fibromyalgia blog here.